Kristen N Ganjoo, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
- Since medical school
- 32 years
- University of South Alabama College of Medicine, 1994
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ganjoo’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A85404 · Current
Licensed to practise in California · since 2003 · expires 2027-11-30 · University of Alabama School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$71,626
Medicare paid this office $71,626 for 205 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 88 | $34,182 | $170 |
| Return visit (30+ min) | 104 | $20,108 | $123 |
| Short return visit (20+ min) | 46 | $4,276 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $3,406 | $106 |
| Long return visit (40+ min) | 15 | $2,878 | $131 |
See all 7 services
| Long return visit (40+ min) | 88 | $34,182 | $170 |
| Return visit (30+ min) | 104 | $20,108 | $123 |
| Short return visit (20+ min) | 46 | $4,276 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $3,406 | $106 |
| Long return visit (40+ min) | 15 | $2,878 | $131 |
| New patient visit (60+ min) | 13 | $2,662 | $205 |
| Return visit (30+ min) | 11 | $968 | $88 |
Who their Medicare patients are
205 Original Medicare patients in 2024. Average age 72 · Under 65 11% · 85 and older 7% · Women 57% · Also on Medicaid 23% · Health risk score 2.44. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 60% · Cancer 46% · Diabetes 26% · Chronic kidney disease 26% · Coronary heart disease 22% · Depression 20% · Atrial fibrillation 19% · Heart failure 16% · COPD 13% · Stroke 8% · Dementia 6%.
The office billed $389,960, Medicare allowed $90,878 and paid $71,626; for 524 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 205 | 524 | 72 | 2.44 | $389,960 | $71,626 |
| 2023 | 233 | 541 | 73 | 2.22 | $325,417 | $54,190 |
| 2022 | 247 | 599 | 73 | 2.32 | $348,781 | $56,865 |
| 2021 | 241 | 695 | 72 | 2.26 | $397,200 | $68,333 |
| 2020 | 199 | 592 | 72 | 2.20 | $248,832 | $42,318 |
| 2019 | 205 | 548 | 71 | 2.08 | $88,450 | $42,887 |
| 2018 | 237 | 651 | 71 | 2.15 | $80,704 | $48,791 |
| 2017 | 246 | 735 | 71 | 2.44 | $172,892 | $58,681 |
| 2016 | 245 | 607 | 70 | 1.90 | $136,075 | $45,169 |
| 2015 | 244 | 665 | 70 | 1.92 | $176,826 | $54,567 |
| 2014 | 280 | 743 | 70 | 2.03 | $223,712 | $65,831 |
| 2013 | 186 | 587 | 69 | 1.85 | $133,343 | $39,365 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 87 | $20,109 | $130 |
| Return visit (30+ min) | 110 | $13,860 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $6,098 | $109 |
| Short return visit (20+ min) | 73 | $5,368 | $58 |
| New patient visit (60+ min) | 23 | $3,841 | $167 |
| New patient visit (45+ min) | 11 | $1,350 | $123 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,096 | $84 |
2022: 9 services
| Long return visit (40+ min) | 54 | $14,676 | $132 |
| Return visit (30+ min) | 88 | $12,783 | $88 |
| Short return visit (20+ min) | 100 | $8,213 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $7,797 | $91 |
| New patient visit (60+ min) | 32 | $5,054 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,755 | $184 |
| New patient visit (45+ min) | 16 | $1,764 | $110 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,447 | $90 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,373 | $98 |
2021: 8 services
| Long return visit (40+ min) | 64 | $17,919 | $134 |
| Return visit (30+ min) | 83 | $14,155 | $90 |
| Short return visit (20+ min) | 111 | $9,478 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $7,923 | $95 |
| New patient visit (60+ min) | 40 | $6,755 | $169 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,701 | $185 |
| Hospital discharge day management, more than 30 minutes | 26 | $2,727 | $101 |
| New patient visit (45+ min) | 16 | $1,841 | $115 |
2020: 9 services
| Short return visit (20+ min) | 114 | $8,361 | $45 |
| Long return visit (40+ min) | 47 | $7,726 | $99 |
| Return visit (30+ min) | 58 | $6,739 | $71 |
| New patient visit (60+ min) | 22 | $3,183 | $145 |
| Short return visit (20+ min) | 24 | $1,437 | $55 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,213 | $101 |
| Return visit (30+ min) | 15 | $1,182 | $79 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $765 | $48 |
| Telehealth originating site facility fee | 13 | $277 | $21 |
2019: 7 services
| Long return visit (40+ min) | 73 | $16,457 | $97 |
| Return visit (30+ min) | 70 | $6,966 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $6,333 | $92 |
| Short return visit (20+ min) | 94 | $5,897 | $43 |
| New patient visit (60+ min) | 12 | $1,828 | $152 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,038 | $86 |
| New patient visit (30+ min) | 11 | $652 | $59 |
2018: 6 services
| Long return visit (40+ min) | 77 | $22,082 | $96 |
| Short return visit (20+ min) | 103 | $8,570 | $43 |
| Return visit (30+ min) | 82 | $7,309 | $64 |
| New patient visit (45+ min) | 19 | $2,075 | $109 |
| New patient visit (60+ min) | 13 | $1,957 | $151 |
| New patient visit (30+ min) | 24 | $1,593 | $66 |
2017: 9 services
| Long return visit (40+ min) | 64 | $15,812 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $10,715 | $90 |
| Return visit (30+ min) | 83 | $9,169 | $65 |
| Short return visit (20+ min) | 89 | $6,363 | $42 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,532 | $181 |
| Hospital discharge day management, more than 30 minutes | 35 | $3,437 | $95 |
| New patient visit (45+ min) | 24 | $2,772 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,958 | $63 |
| New patient visit (30+ min) | 17 | $1,154 | $68 |
2016: 8 services
| Return visit (30+ min) | 92 | $10,985 | $66 |
| Long return visit (40+ min) | 48 | $7,634 | $95 |
| Short return visit (20+ min) | 86 | $7,476 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $5,860 | $92 |
| New patient visit (45+ min) | 37 | $4,222 | $114 |
| New patient visit (60+ min) | 21 | $3,144 | $150 |
| New patient visit (30+ min) | 22 | $1,492 | $68 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,361 | $97 |
2015: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $12,118 | $93 |
| Return visit (30+ min) | 88 | $10,920 | $66 |
| Long return visit (40+ min) | 33 | $7,253 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,254 | $181 |
| Short return visit (20+ min) | 86 | $5,052 | $40 |
| New patient visit (60+ min) | 33 | $4,717 | $143 |
| Hospital discharge day management, more than 30 minutes | 34 | $3,327 | $98 |
| New patient visit (45+ min) | 24 | $2,701 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,556 | $65 |
2014: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 75 | $17,836 | $92 |
| Return visit (30+ min) | 101 | $10,253 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,228 | $179 |
| Hospital discharge day management, more than 30 minutes | 71 | $6,946 | $96 |
| Long return visit (40+ min) | 36 | $5,864 | $96 |
| New patient visit (60+ min) | 35 | $5,004 | $143 |
| Short return visit (20+ min) | 58 | $3,402 | $40 |
| New patient visit (45+ min) | 19 | $2,197 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,050 | $64 |
2013: 8 services
| Short return visit (20+ min) | 108 | $8,674 | $40 |
| Return visit (30+ min) | 60 | $8,196 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $7,577 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,769 | $171 |
| New patient visit (45+ min) | 28 | $3,163 | $113 |
| New patient visit (60+ min) | 13 | $1,857 | $143 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,709 | $95 |
| Long return visit (40+ min) | 16 | $1,677 | $76 |
Medicaid work
$2,236 in 2023
Medicaid paid $2,236 for 46 billed services this clinician did in 2023, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 15 | $1,118 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $1,117 |
| 2023 | 46 | 2 | 15 | $2,236 |
| 2022 | 93 | 2 | 16 | $5,613 |
| 2021 | 75 | 2 | 15 | $4,379 |
| 2020 | 27 | 1 | 13 | $822 |
See the largest Medicaid services in earlier years
2022
| Long return visit (40+ min) | 47 | $3,088 |
| Return visit (30+ min) | 46 | $2,525 |
2021
| Return visit (30+ min) | 46 | $2,954 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 29 | $1,425 |
2020
| Short return visit (20+ min) | 27 | $822 |
Drugs they prescribed that Part D paid
$1,595,318
Pharmacies billed $1,595,318 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 11% of their Part D prescriptions (75 of 681) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%. Long-acting opioids: 55% of their opioid prescriptions.
516 generic and fewer than 11 brand-name prescriptions · $1,595,318 in drug cost · 21 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Qinlock | 17 | $715,457 | $42,086 |
| Lynparza | 16 | $221,032 | $13,814 |
| Pazopanib | 11 | $65,316 | $5,938 |
| Imatinib Mesylate | 24 | $31,705 | $1,321 |
| Eliquis | 25 | $15,747 | $630 |
See all 19 drugs
| Qinlock | 17 | $715,457 | $42,086 |
| Lynparza | 16 | $221,032 | $13,814 |
| Pazopanib | 11 | $65,316 | $5,938 |
| Imatinib Mesylate | 24 | $31,705 | $1,321 |
| Eliquis | 25 | $15,747 | $630 |
| Xarelto | 15 | $12,571 | $838 |
| Fentanyl | 19 | $1,140 | $60 |
| Levothyroxine | 30 | $466 | $16 |
| Pregabalin | 13 | $432 | $33 |
| Escitalopram | 13 | $345 | $27 |
| Oxycodone | 19 | $300 | $16 |
| Gabapentin | 18 | $272 | $15 |
| Methadone | 11 | $206 | $19 |
| Prednisone | 34 | $159 | $5 |
| Omeprazole | 15 | $149 | $10 |
| Anastrozole | 16 | $137 | $9 |
| Ondansetron | 20 | $100 | $5 |
| Duloxetine | 11 | $89 | $8 |
| Famotidine | 22 | $39 | $2 |
Year by year
| 2024 | 681 | 92 | 11% (75) | None | $1,595,318 |
| 2023 | 526 | 93 | 14% (71) | None | $1,434,476 |
| 2022 | 730 | 108 | 9% (68) | None | $1,743,951 |
| 2021 | 712 | 102 | 11% (81) | None | $2,215,535 |
| 2020 | 702 | 99 | 11% (80) | None | $823,678 |
| 2019 | 548 | 105 | 9% (47) | 21% | $895,251 |
| 2018 | 489 | 90 | 11% (52) | None | $616,160 |
| 2017 | 480 | 98 | 12% (58) | None | $294,270 |
| 2016 | 388 | 70 | 14% (55) | None | $534,394 |
| 2015 | 233 | 59 | 9% (20) | 24% | $330,257 |
| 2014 | 290 | 73 | 13% (37) | None | $249,684 |
| 2013 | 250 | 48 | 8% (20) | None | $424,644 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Qinlock | 15 | $601,572 | $40,105 |
| Stivarga | 20 | $205,122 | $10,256 |
| Imatinib Mesylate | 57 | $117,367 | $2,059 |
| Xarelto | 20 | $13,905 | $695 |
| Eliquis | 22 | $13,536 | $615 |
| Gabapentin | 16 | $585 | $37 |
| Methadone | 24 | $491 | $20 |
| Pregabalin | 13 | $392 | $30 |
| Oxycodone | 15 | $218 | $15 |
| Prochlorperazine Maleate | 14 | $184 | $13 |
| Hydrocodone-Acetaminophen | 13 | $175 | $13 |
| Ondansetron | 20 | $171 | $9 |
| Levothyroxine | 12 | $119 | $10 |
2022: 21 drugs
| Qinlock | 13 | $489,679 | $37,668 |
| Pomalyst | 11 | $358,759 | $32,614 |
| Ibrance | 21 | $314,822 | $14,992 |
| Imatinib Mesylate | 28 | $84,597 | $3,021 |
| Eliquis | 21 | $12,243 | $583 |
| Xarelto | 11 | $6,396 | $581 |
| Ondansetron Odt | 22 | $800 | $36 |
| Gabapentin | 33 | $723 | $22 |
| Ondansetron | 30 | $717 | $24 |
| Omeprazole | 25 | $439 | $18 |
| Oxycodone | 22 | $421 | $19 |
| Prochlorperazine Maleate | 24 | $352 | $15 |
| Fludrocortisone Acetate | 11 | $231 | $21 |
| Pantoprazole | 19 | $214 | $11 |
| Methadone | 13 | $204 | $16 |
| Olanzapine | 13 | $198 | $15 |
| Losartan | 15 | $189 | $13 |
| Levothyroxine | 22 | $167 | $8 |
| Prednisone | 25 | $145 | $6 |
| Famotidine | 14 | $112 | $8 |
| Furosemide | 13 | $16 | $1 |
2021: 19 drugs
| Qinlock | 17 | $581,866 | $34,227 |
| Ibrance | 21 | $293,502 | $13,976 |
| Sutent | 18 | $245,771 | $13,654 |
| Xarelto | 11 | $6,313 | $574 |
| Eliquis | 11 | $5,348 | $486 |
| Imatinib Mesylate | 16 | $5,226 | $327 |
| Pregabalin | 19 | $1,628 | $86 |
| Ondansetron | 40 | $1,196 | $30 |
| Gabapentin | 29 | $716 | $25 |
| Oxycodone | 30 | $418 | $14 |
| Omeprazole | 32 | $384 | $12 |
| Dexamethasone | 13 | $319 | $25 |
| Famotidine | 22 | $307 | $14 |
| Prochlorperazine Maleate | 21 | $288 | $14 |
| Escitalopram | 11 | $181 | $16 |
| Prednisone | 20 | $156 | $8 |
| Losartan | 14 | $85 | $6 |
| Pantoprazole | 11 | $57 | $5 |
| Lorazepam | 13 | $35 | $3 |
2020: 22 drugs
| Stivarga | 13 | $196,316 | $15,101 |
| Votrient | 11 | $116,481 | $10,589 |
| Retacrit | 11 | $20,248 | $1,841 |
| Imatinib Mesylate | 29 | $13,550 | $467 |
| Pregabalin | 18 | $1,396 | $78 |
| Acyclovir | 18 | $1,063 | $59 |
| Morphine Sulfate Er | 11 | $987 | $90 |
| Lidocaine | 11 | $884 | $80 |
| Ondansetron | 43 | $817 | $19 |
| Sodium Chloride | 19 | $595 | $31 |
| Diphenoxylate-Atropine | 12 | $520 | $43 |
| Levothyroxine | 30 | $442 | $15 |
| Oxycodone | 22 | $422 | $19 |
| Gabapentin | 24 | $412 | $17 |
| Anastrozole | 18 | $316 | $18 |
| Famotidine | 16 | $228 | $14 |
| Escitalopram | 12 | $173 | $14 |
| Omeprazole | 22 | $173 | $8 |
| Pantoprazole | 13 | $153 | $12 |
| Zolpidem | 13 | $93 | $7 |
| Prednisone | 14 | $67 | $5 |
| Lorazepam | 11 | $31 | $3 |
2019: 14 drugs
| Votrient | 37 | $389,975 | $10,540 |
| Imatinib Mesylate | 20 | $70,130 | $3,506 |
| Ondansetron | 36 | $680 | $19 |
| Lidocaine | 13 | $642 | $49 |
| Levothyroxine | 15 | $345 | $23 |
| Anastrozole | 21 | $307 | $15 |
| Gabapentin | 19 | $286 | $15 |
| Omeprazole | 15 | $194 | $13 |
| Oxycodone | 11 | $185 | $17 |
| Prednisone | 21 | $183 | $9 |
| Prochlorperazine Maleate | 12 | $168 | $14 |
| Pantoprazole | 19 | $149 | $8 |
| Losartan | 12 | $120 | $10 |
| Lorazepam | 15 | $89 | $6 |
2018: 11 drugs
| Votrient | 28 | $263,324 | $9,404 |
| Imatinib Mesylate | 26 | $200,007 | $7,693 |
| Xarelto | 11 | $7,221 | $656 |
| Ondansetron | 35 | $999 | $29 |
| Gabapentin | 23 | $356 | $15 |
| Pantoprazole | 25 | $285 | $11 |
| Prochlorperazine Maleate | 16 | $283 | $18 |
| Oxycodone | 12 | $206 | $17 |
| Omeprazole | 17 | $186 | $11 |
| Prednisone | 22 | $171 | $8 |
| Lorazepam | 15 | $97 | $6 |
2017: 10 drugs
| Imatinib Mesylate | 22 | $194,898 | $8,859 |
| Ondansetron | 26 | $703 | $27 |
| Oxycodone | 23 | $508 | $22 |
| Gabapentin | 24 | $314 | $13 |
| Prochlorperazine Maleate | 23 | $267 | $12 |
| Omeprazole | 24 | $181 | $8 |
| Anastrozole | 11 | $93 | $8 |
| Lorazepam | 15 | $78 | $5 |
| Prednisone | 15 | $75 | $5 |
| Lisinopril | 13 | $23 | $2 |
2016: 9 drugs
| Imatinib Mesylate | 17 | $171,578 | $10,093 |
| Votrient | 14 | $135,284 | $9,663 |
| Ondansetron | 25 | $920 | $37 |
| Gabapentin | 22 | $339 | $15 |
| Tamoxifen Citrate | 11 | $275 | $25 |
| Oxycodone | 11 | $267 | $24 |
| Prochlorperazine Maleate | 19 | $224 | $12 |
| Hydromorphone | 13 | $168 | $13 |
| Omeprazole | 16 | $137 | $9 |
2015: 4 drugs
| Gleevec | 24 | $275,863 | $11,494 |
| Ondansetron | 24 | $782 | $33 |
| Gabapentin | 17 | $148 | $9 |
| Lorazepam | 15 | $103 | $7 |
2014: 7 drugs
| Gleevec | 20 | $185,428 | $9,271 |
| Hydrocodone-Acetaminophen | 15 | $890 | $59 |
| Ondansetron | 19 | $626 | $33 |
| Gabapentin | 29 | $261 | $9 |
| Metoprolol | 12 | $203 | $17 |
| Omeprazole | 11 | $100 | $9 |
| Famotidine | 14 | $91 | $6 |
2013: 7 drugs
| Gleevec | 15 | $232,448 | $15,497 |
| Afinitor | 13 | $102,909 | $7,916 |
| Ondansetron | 13 | $720 | $55 |
| Hydrocodone-Acetaminophen | 14 | $653 | $47 |
| Gabapentin | 17 | $213 | $13 |
| Potassium Chloride | 12 | $162 | $14 |
| Amlodipine Besylate | 13 | $119 | $9 |
Money from drug and device companies
$2,960 in 2024
| 2024 | 1 | 1 | $2,960 | $2,960 |
| 2023 | 2 | 10 | $6,171 | $7,836 |
| 2022 | 1 | 4 | $2,425 | $2,553 |
| 2020 | 3 | 14 | $14,660 | $16,978 |
| 2019 | 1 | 5 | None | $836 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | None | $2,960 | 1 payment
|
See the published payment
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2024-01-09 | None | $2,960 |
See earlier years (2023, 2022, 2020, 2019)
2023: $7,836
| Deciphera Pharmaceuticals | Qinlock | $5,326 | 7 payments
|
| Daiichi Sankyo | Turalio | $2,510 | 3 payments
|
2022: $2,553
| Daiichi Sankyo | Turalio | $2,553 | 4 payments
|
2020: $16,978
| Daiichi Sankyo | Turalio | $7,246 | 8 payments
|
| Foundation Medicine | Foundationact | $5,882 | 5 payments
|
| Deciphera Pharmaceuticals | Qinlock | $3,850 | 1 payment
|
2019: $836
| Lilly USA | None | $836 | 5 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2020 | Their institution | $1,089,984 |
| Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1/ Tsc2 Genes (Precision 1) · 2023 | Their institution | $907,953 |
| PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2023 | Their institution | $337,642 |
| Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes. · 2023 | Their institution | $244,745 |
| Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2024 | Their institution | $242,624 |
| PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2024 | Their institution | $238,761 |
| Merck Sharp & Dohme Corporation · A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934,V935 Htert Vaccination in Cancer Patients With Selected Solid Tumors · 2019 | Their institution | $160,302 |
| Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2023 | Their institution | $129,078 |
| PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2025 | Their institution | $102,719 |
| Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2025 | Their institution | $94,714 |
| GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2022 | Their institution | $93,631 |
| Karyopharm Therapeutics Inc. · Xpovio · 2020 | Their institution | $90,576 |
| Deciphera Pharmaceuticals Inc. · Intrigue A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib Intrigue · 2021 | Their institution | $82,310 |
| Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1tsc2 Genes Precision 1 · 2024 | Their institution | $75,252 |
| Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2021 | Their institution | $67,804 |
| Deciphera Pharmaceuticals Inc. · Intrigue A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib Intrigue · 2022 | Their institution | $64,063 |
| Karyopharm Therapeutics Inc. · A Phase 2-3 Multicenter, Randomized, Double-Blind Study of Selinexor (Kpt-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (Ddls) · 2021 | Their institution | $45,769 |
| Daiichi Sankyo Inc. · Turalio · 2019 | Their institution | $43,831 |
| Daiichi Sankyo Inc. · Pl3397-A-U126 · 2019 | Their institution | $42,516 |
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2022 | Their institution | $41,653 |
| GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2021 | Their institution | $39,014 |
| Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2024 | Their institution | $33,974 |
| GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2024 | Their institution | $32,567 |
| Daiichi Sankyo Inc. · Pl3397-A-U126 · 2020 | Their institution | $32,155 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced Or Metastatic Soft Tissue Sarcoma · 2019 | Their institution | $31,511 |
| Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2025 | Their institution | $31,455 |
| PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2022 | Their institution | $30,109 |
| GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2023 | Their institution | $28,922 |
| Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes. · 2022 | Their institution | $28,655 |
| GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2020 | Their institution | $24,263 |
| GlaxoSmithKline, LLC. · Long Term Follow-Up of Participants Exposed To Gsk3377794 (Ny-Eso-1c25 · 2022 | Their institution | $23,430 |
| Deciphera Pharmaceuticals Inc. · Intrigue A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib Intrigue · 2020 | Their institution | $22,662 |
| Daiichi Sankyo Inc. · Pl3397-A-U126 · 2021 | Their institution | $22,042 |
| Aadi Bioscience, Inc. · A Phase 2 Study of Abi-009 in Patients With Advanced Malignant Pecoma · 2022 | Their institution | $21,943 |
| Deciphera Pharmaceuticals Inc. · A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib (Intrigue) · 2023 | Their institution | $20,894 |
| Deciphera Pharmaceuticals Inc. · A Multicenter Phase 1/2, Open-Label Study of Dcc-3014 To Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2022 | Their institution | $19,779 |
| Daiichi Sankyo Inc. · Turalio · 2022 | Their institution | $18,160 |
| Daiichi Sankyo Inc. · Turalio · 2020 | Their institution | $15,554 |
| E.R. Squibb & Sons, L.L.C. · Phase II Study of Ipilimumab Plus Nivolumab in Combination With Cryotherapy in Metastatic Or Locally Advanced Soft Tissue Sarcoma · 2023 | Their institution | $15,000 |
| GlaxoSmithKline, LLC. · Long Term Follow-Up of Participants Exposed To Gsk3377794 (Ny-Eso-1c25 · 2023 | Their institution | $12,160 |
| Deciphera Pharmaceuticals Inc. · A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib (Intrigue) · 2024 | Their institution | $9,024 |
| Adaptimmune LLC · Master Protocol To Assess the Safety and Antitumor Activity of Genetically Engineered Ny-Eso-1-Specific (C259) T Cells, Alone Or in Combination With Other Agents, in Hla-A2+ Participants With Ny-Eso-1 and/Or Lage-1a Positive Solid Tumors (Ignyte-Eso) · 2025 | Their institution | $7,680 |
| Daiichi Sankyo Inc. · Pl3397au126 · 2019 | Their institution | $7,047 |
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2021 | Their institution | $4,928 |
| Daiichi Sankyo Inc. · Pl3397-A-U126 · 2022 | Their institution | $4,510 |
| Daiichi Sankyo Inc. · Turalio · 2021 | Their institution | $3,968 |
| Deciphera Pharmaceuticals Inc. · Invictus A Phase 3 Interventional Double-Blind Placebo-Controlled Study To Assess the Safety and Efficacy of Dcc-2618 in Patients With Advanced Gastrointestinal Stromal Tumors Who Have Received Treatment With Prior Anticancer Therapies · 2022 | Their institution | $1,600 |
| GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2019 | This clinician | $1,155 |
| Merck Sharp & Dohme Corporation · A Randomized, Open-Label, Phase 2 Trial of Cmb305 Sequentially Administered Lv305 and G305 and Atezolizumab in Patients With Locally Advanced, Relapsed, Or Metastatic Sarcoma Expressing Ny-Eso-1 · 2019 | Their institution | $544 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1669563391
- Licence
- CA A85404California A85404: Current · expires 2027-11-30
- Trained
- University of South Alabama College of Medicine, 1994 · 32 years ago
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-09-27
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 875 Blake Wilbur Drive, Stanford, CA, 94305